Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 7/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16461592 | 0.87 | PIK3CA (0.37) | PIK3CAMTORNPC1RAB9ACREBBP | |
| SCHEMBL857325 | 0.84 | PIK3CA (0.44) | PIK3CANPC1RAB9ASMN1; SMN2GPR142 | |
| SCHEMBL856444 | 0.79 | PIK3CA (0.45) | PIK3CAMTORGPR142CREBBP | |
| SCHEMBL3756231 | 0.79 | PIK3CA (0.70) | PIK3CAMTORGPR142CREBBP | |
| SCHEMBL856320 | 0.77 | PIK3CA (0.49) | PIK3CAMTORGPR142CREBBP | |
| SCHEMBL3749745 | 0.77 | PIK3CA (0.49) | PIK3CAMTORGPR142 | |
| SCHEMBL3752728 | 0.77 | PIK3CA (0.62) | PIK3CAMTORGPR142CREBBP | |
| SCHEMBL30405764 | 0.77 | PIK3CA (0.62) | PIK3CAMTORGPR142CREBBP | |
| Hydrochloric Acid SCHEMBL8513371 | 0.76 | NPC1 (0.44) | PIK3CANPC1RAB9ASMN1; SMN2PIK3CG | |
| SCHEMBL2724334 | 0.75 | PIK3CA (0.47) | PIK3CAMTORGPR142CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2643327-A1 | BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071511-A1 | BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RICTOR, RPTOR | PIK3CA 135/4885MTOR 1/4885NPC1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.